Advanced search×

Early effect of peginterferon alpha-2b plus ribavirin treatment on blood pressure and insulin resistance in patients with chronic hepatitis C.

Muharrem M Taskoparan, Ender E Serin, Huseyin Savas HS Gokturk, Mustafa Okan MO Icer, Kutlu K Abaci, Birol B Ozer, Aysegul A Zumrutdal, and Ugur U Yilmaz

Hepatogastroenterology 58(107-108):875-9 (2011) PMID 21830408

To investigate the early effects of peginterferon alpha-2b plus ribavirin therapy on blood pressure and related cardiovascular risk parameters, and also insulin resistance in patients with chronic hepatitis C virus (HCV) infection.

Version: za2963e q8zae q8zb5 q8zca q8zd3 q8zed q8zf4 q8zg2
Buy PDF

Similar articles you may find interesting…

  1. Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile acr...
    S De Meyer, A Ghys, and G Picchio

    J Viral Hepat 20(6):395-403 (2013) PMID 23647956

    Study C209 evaluated the activity of telaprevir in treatment-naïve patients with genotypes 2 or 3 (G2, G3) hepatitis C virus (HCV) infection. Telaprevir monotherapy showed potent activity against HCV G2, but limited activity against G3. This analysis was performed to characterize HC...
    Buy PDF
  2. Scaffolding Proteins DLG1 and CASK Cooperate to Maintain the Nephron Progenitor Population during Kidney Development.
    Sun-Young Ahn, Yeawon Kim, and Jeffrey H Miner

    J Am Soc Nephrol (2013) PMID 23661808

    We generated mice deficient in both DLG1 and CASK either 1) globally, 2) in metanephric mesenchyme, or 3) in nephron progenitors. With each approach, Dlg1;Cask double-knockout (DKO) kidneys were severely hypoplastic and dysplastic and demonstrated rapid, premature depletion of nephron progenitors/st...
    Buy PDF
  3. Phase I pharmacokinetic and biodistribution study with escalating doses of (223)Ra-dichloride in men with castration-resistant metastatic pr...
    Jorge A Carrasquillo, Joseph A O'Donoghue, and Michael J Morris

    Eur J Nucl Med Mol Imaging (2013) PMID 23653243

    Pharmacokinetic studies showed rapid clearance of (223)Ra from the vasculature, with a median of 14 % (range 9-34 %), 2 % (range 1.6-3.9 %), and 0.5 % (range 0.4-1.0 %) remaining in plasma at the end of infusion, after 4 h, and after 24 h, respectively. Biodistribution studies showed early p...
    Buy PDF